E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Hemoglobinuria paroxística nocturna (HPN) |
|
E.1.1.1 | Medical condition in easily understood language |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Hemoglobinuria paroxística nocturna (HPN) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10055629 |
E.1.2 | Term | Paroxysmal nocturnal hemoglobinuria |
E.1.2 | System Organ Class | 100000004857 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Efficacy of ALXN1210 |
Eficacia de ALXN1210 |
|
E.2.2 | Secondary objectives of the trial |
Safety and tolerability of ALXN1210 Additional efficacy measures |
Seguridad y tolerabilidad de ALXN1210 Medidas adicionales de eficacia |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female ≥ 18 years of age 2. Treated with eculizumab for PNH for at least 6 months prior to Day 1 3. Lactate dehydrogenase (LDH) ≤ 1.5 x upper limit of normal (ULN) at Screening 4. PNH diagnosis confirmed by documented by high-sensitivity flow cytometry 5. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment. 6. Female patients of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ALXN1210 7. Willing and able to give written informed consent and comply with study visit schedule |
1. Varones o mujeres de 18 años de edad o mayores 2. Deben estar en tratamiento con eculizumab para la HPN durante al menos 6 meses antes del día 1. 3. Lactato deshidrogenasa (LDH) ≤1,5 X límite superior de la normalidad (LSN) en la selección. 4. Diagnóstico documentado de HPN, confirmado mediante evaluación por citometría de flujo de alta sensibilidad 5. Vacuna documentada contra la meningitis meningocócica durante los 3 años antes de, o en el momento de, iniciar el fármaco del estudio. 6. Las mujeres en edad fértil y los pacientes varones con parejas femeninas en edad fértil deben utilizar métodos efectivos de anticoncepción desde la selección y durante 8 meses después de la última dosis de ALXN1210 7. Los pacientes deben estar dispuestos y ser capaces de dar su consentimiento informado por escrito y de cumplir con todas las visitas y procedimientos del estudio |
|
E.4 | Principal exclusion criteria |
1. History of bone marrow transplantation 2. Body weight < 40 kilograms 3. History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the investigator or sponsor, would preclude participation. 4. Unstable medical conditions (eg, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within 6 months of randomization, coexisting chronic anemia unrelated to PNH) 5. Females who are pregnant, breastfeeding or who have a positive pregnancy test at screening or Day 1 6. Participation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that investigational product, whichever is greater. |
1. Antecedentes de trasplante de médula ósea. 2. Peso <40 kg en la selección. 3. Antecedentes de enfermedad cardíaca, pulmonar, renal, endocrina o hepática que, en opinión del investigador o del promotor, impida la participación 4. Afecciones médicas inestables (p. ej., isquemia miocárdica, hemorragia digestiva activa, insuficiencia cardíaca congestiva grave, necesidad prevista de cirugía mayor en el plazo de 6 meses antes de la aleatorización, anemia crónica concomitante no relacionada con la HPN) 5. Mujeres que estén embarazadas, en periodo de lactancia o que tienen un resultado positivo en la prueba de embarazo en la selección o el día 1. 6. Participación en otro estudio de intervención con tratamiento o uso de cualquier tratamiento experimental en los 30 días anteriores al inicio del fármaco del estudio el día 1 de este estudio o durante 5 semividas de dicho producto en fase de investigación, lo que sea mayor. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Hemolysis as directly measured by lactate dehydrogenase percent change (LDH-PCHG) |
Hemólisis medida directamente por la variación porcentual en la lactato deshidrogenasa (LDH-PCHG) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Change from baseline in quality of life (QoL) as assessed by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue - Percentage of patients who achieve transfusion avoidance (TA) - Proportion of patients with stabilized hemoglobin |
- Variación en la calidad de vida (CdV) evaluada mediante la escala de Evaluación funcional para el tratamiento de enfermedades crónicas (FACIT)-Fatiga - Porcentaje de pacientes que logren ausencia de transfusión (AT) - Proporción de pacientes con hemoglobina estabilizada |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS in the extension period |
LVLS en el preiodo de extensión |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |